Caspofungin or Micafungin as Empiric Antifungal Therapy for Persistent Fever and Neutropenia
Evaluation of Caspofungin or Micafungin as Empiric Antifungal Therapy in Adult Patients With Persistent Febrile Neutropenia: A Retrospective, Observational, Sequential Cohort Analysis
Sponsor: Astellas Pharma US, Inc.
A observational or N/A phase clinical study on Febrile Neutropenia, this trial is completed. The trial is conducted by Astellas Pharma US, Inc. and has accumulated 9 data snapshots since 2008. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Jan 2023 — Jul 2024 [monthly]
Completed
-
Dec 2022 — Jan 2023 [monthly]
Completed
-
Dec 2021 — Dec 2022 [monthly]
Completed
▶ Show 4 earlier versions
-
Jan 2021 — Dec 2021 [monthly]
Completed
-
Jun 2018 — Jan 2021 [monthly]
Completed
-
Apr 2018 — Jun 2018 [monthly]
Completed
Phase: NA → None
-
Jan 2017 — Apr 2018 [monthly]
Completed NA
First recorded
Jan 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Astellas Pharma US, Inc.
- Brigham and Women's Hospital
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Boston, United States